by plexusventures_h3tnl0 | Jan 19, 2017 | Uncategorized
London, United Kingdom – Plexus Ventures is pleased to announce it served as advisor to Celon Pharma SA and Polfarmex SA in the out-licensing of Salmex® Orbicel® (fluticasone/salmeterol), a generic version of GSK’s Advair® Diskus®, to an undisclosed company for...
by plexusventures_h3tnl0 | Nov 8, 2016 | Uncategorized
Philadelphia, Pennsylvania – Plexus Ventures is pleased to announce it served as advisor to Mabion S.A. in the out-licensing of Mabion CD20 (Rituximab Biosimilar) European rights to Mylan Ireland Limited. Michael O’Sullivan, Managing Partner of Plexus Ventures’...
by plexusventures_h3tnl0 | Oct 27, 2015 | Uncategorized
Philadelphia, Pennsylvania – Plexus Ventures announces the successful completion of a recent out-licensing project on behalf of Celon Pharma. Additional details regarding the transaction, taken from Glenmark’s October 23, 2015 press release are included below:...
by plexusventures_h3tnl0 | Oct 23, 2015 | Uncategorized
Philadelphia, PA – Plexus Ventures LLC, a leading global pharmaceutical business development consultancy, announced today that Gabriele Tundo has joined the firm as an Associate. Gabriele Tundo, a native Italian, joined Plexus Ventures in October, 2015 and is...
Recent Comments